/ /

LATEST

Inverted ILM flap technique improves outcomes of macular hole surgery
Surveying the artificial tear landscapePatients use artificial tears for different reasons and diverse conditions. While available products supplement tear production and provide relief, few distinctions between drops have been clearly established. Recent studies show that direct comparison of a new product to an older, established one and use of “real-world” metrics can be most useful to prescribers.
Intranasal neurostimulation yields positive results for dry eye diseaseThe first portable, external neurostimulator to be approved in eye care stimulates endogenous tear production without physical irritation. The device can dramatically reduce symptoms and may enable patients to stop use of some or all tear substitutes or medications, noted John Sheppard, MD, MMSc.
Complicated cataracts pose almost no limits for adding MIGSComorbidity of glaucoma poses some increased risks for cataract surgery, but even when there are intraoperative complications during the lens removal procedure, it is almost always possible to still add micro-invasive glaucoma surgery (MIGS), said Reay H. Brown, MD.
PRK enhancement after SMILE favorable after short follow-upSurface ablation performed with mitomycin-C (MMC) seems to be a safe and effective technique for treating residual refractive error after myopic SMILE, said Martin Dirisamer, MD.
OCTA: Future Is bright, fast, and wide in ROPAdvances in optical coherence tomography (OCT) and OCT angiography (OCTA) may enable more objective and accurate diagnosis of ROP in the future.
Subretinal therapy offers promise of lighter treatment burden for AMDRGX-314 gene therapy offers patients the potential for a lower treatment burden with one subretinal injection of a gene therapy delivering an anti-vascular endothelial growth factor protein.
Ziv-aflibercept for DME provides BCVA gains, lower dosing burdenResults of a 1-year randomized controlled trial investigating treatment for diabetic macular edema (DME) show that intravitreal ziv-aflibercept (Zaltrap, Sanofi Genzyme) 1.25 or 2.5 mg is safe, according to Masoud Soheilian, MD.
Intranasal neurostimulator shows benefit for increasing tear productionResults from two pivotal multicenter trials demonstrate that an intranasal tear neurostimulator (TrueTear, Allergan) safely and effectively increases endogenous tear production in patients with dry eye disease (DED), said Edward Holland, MD.
IRIS Registry gives glimpse into DME in real worldAn analysis of data collected in the Intelligent Research in Sight (IRIS) Registry suggests that in the real-world setting, newly diagnosed diabetic macular edema (DME) is being vastly undertreated. Not only are the majority of these patients not receiving active intervention, but those who are started on anti-vascular endothelial growth factor (VEGF) therapy seem to be getting a suboptimal number of injections, said Jeffrey R. Willis, MD, PhD.

Poll

View Results